FDA Delays Final Approval of Novavax COVID Vaccine
The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal approval for mRNA-based COVID shots, which President Donald Trump has touted as a key first- term achievement.
It reported revenues of 38.41 million yuan in the first half of 2024 and a net loss of 903 million yuan, hit by falling ...
Novavax reached a settlement with Gavi, the Vaccine Alliance, after t | International vaccine partnership Gavi has ...
Novavax (NVAX) stock rebounds 2.5% after six days of losses amid FDA approval delays for its COVID-19 vaccine.
Novavax (NasdaqGS:NVAX) recently experienced a significant decline of 21% over the past week, coinciding with leadership changes, including the retirement of longtime Chairman James Young and the ...
Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...
We recently curated a list of 11 High-Risk High-Reward Growth Stocks To Buy Now. Here, we take a detailed look at Novavax, ...
One in four Republican parents is now skipping or delaying some childhood vaccines for their kids, such as the MMR vaccine ...
The forced resignation of FDA vaccine regulator Peter Marks has, in part, sparked anxiety in Big Pharma investors, as shares in Moderna and Novavax slide. Marks’ departure comes amid a sweeping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback